View in EDS PDF Full Text

5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.

Saved in:
Bibliographic Details
Title: 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
Authors: Velcheti V; Perlmutter Cancer Center, New York University Langone Health, New York, NY., Rai P; Merck & Co., Inc., Rahway, NJ. Electronic address: pragya.rai@merck.com., Kao YH; Merck & Co., Inc., Rahway, NJ., Chirovsky D; Merck & Co., Inc., Rahway, NJ., Nunes AT; Merck & Co., Inc., Rahway, NJ., Liu SV; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Source: Clinical lung cancer [Clin Lung Cancer] 2024 Sep; Vol. 25 (6), pp. 502-508.e3. Date of Electronic Publication: 2024 May 16.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38880664
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Velcheti+V%22">Velcheti V</searchLink>; Perlmutter Cancer Center, New York University Langone Health, New York, NY.<br /><searchLink fieldCode="AU" term="%22Rai+P%22">Rai P</searchLink>; Merck & Co., Inc., Rahway, NJ. Electronic address: pragya.rai@merck.com.<br /><searchLink fieldCode="AU" term="%22Kao+YH%22">Kao YH</searchLink>; Merck & Co., Inc., Rahway, NJ.<br /><searchLink fieldCode="AU" term="%22Chirovsky+D%22">Chirovsky D</searchLink>; Merck & Co., Inc., Rahway, NJ.<br /><searchLink fieldCode="AU" term="%22Nunes+AT%22">Nunes AT</searchLink>; Merck & Co., Inc., Rahway, NJ.<br /><searchLink fieldCode="AU" term="%22Liu+SV%22">Liu SV</searchLink>; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100893225%22">Clinical lung cancer</searchLink> [Clin Lung Cancer] 2024 Sep; Vol. 25 (6), pp. 502-508.e3. <i>Date of Electronic Publication: </i>2024 May 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100893225 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0690 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215257304%22">15257304 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lung Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38880664
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.cllc.2024.05.002
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 502
    Titles:
      – TitleFull: 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Velcheti V
      – PersonEntity:
          Name:
            NameFull: Rai P
      – PersonEntity:
          Name:
            NameFull: Kao YH
      – PersonEntity:
          Name:
            NameFull: Chirovsky D
      – PersonEntity:
          Name:
            NameFull: Nunes AT
      – PersonEntity:
          Name:
            NameFull: Liu SV
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2024 Sep
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1938-0690
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Clinical lung cancer
              Type: main
ResultId 1